Publications by authors named "Judith Melchior Haissman"
Real-world outcomes following third or subsequent lines of therapy: A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas.
Ahmed Ludvigsen Al-Mashhadi Lasse Hjort Jakobsen Peter Brown Anne Ortved Gang Anne-Luise Thorsteinsson Judith Melchior Haissman
Br J Haematol
March 2024
Article Synopsis
- Outcome data for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), especially beyond second-line therapy, is limited outside of clinical trials, making real-world context important.
- A study in Denmark reviewed medical records of 3753 adults with DLBCL, focusing on 189 patients who received third-line treatment or beyond, with a median age of 71 years and various treatment options including supportive care and clinical trials.
- Overall survival rates were low, with 2-year estimates at 25% for all patients and 49% for those receiving platinum-based salvage therapy, while certain factors like age, CNS involvement, and elevated LDH indicated poorer outcomes.